Cervomed Inc (CRVO) Stock Price, Quote & News

Company Profile

CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurologic...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 744 4400

Website: www.cervomed.com

Address:

20 Park Plaza, Suite 424, Boston, United States

Doki0926 Nov. 13 at 10:08 AM

$CRVO will it go up?

0 · Reply

BPler Nov. 12 at 9:03 PM

$CRVO https://www.marketbeat.com/instant-alerts/cervomed-inc-nasdaqcrvo-receives-consensus-rating-of-moderate-buy-from-brokerages-2025-11-12/

0 · Reply

5layer Nov. 12 at 2:02 PM

$CRVO

0 · Reply

BPler Nov. 12 at 7:02 AM

$CRVO https://beingpatient.com/dementia-with-lewy-bodies-pill-phase-3-clinical-trial/?utm_source=organic&utm_medium=social

1 · Reply

BPler Nov. 12 at 7:00 AM

$CRVO https://www.gurufocus.com/news/3201183/crvo-analyst-jason-kolbert-maintains-buy-rating-with-31-target-crvo-stock-news

0 · Reply

MV0527 Nov. 12 at 1:56 AM

$CRVO

0 · Reply

5layer Nov. 11 at 5:04 PM

$CRVO

1 · Reply

Messerschmittbf109 Nov. 11 at 3:24 PM

$CRVO $JSPR boys .. but really are you thinking positive in this turd full of thi eves ?????

0 · Reply

Messerschmittbf109 Nov. 11 at 1:37 PM

$CRVO rottens tp 4-5 x actual price Rottens

0 · Reply

MV0527 Nov. 11 at 1:15 PM

$CRVO

0 · Reply

CervoMed to Present at the Emerging Growth Conference

Oct 8, 2025, 11:54 AM EDT - 5 weeks ago

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

Oct 8, 2025, 7:00 AM EDT - 5 weeks ago

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Oct 2, 2025, 8:00 AM EDT - 6 weeks ago

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Sep 17, 2025, 7:30 AM EDT - 2 months ago

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

Sep 3, 2025, 8:00 AM EDT - 2 months ago

CervoMed to Participate in Upcoming Investor Conferences

Jul 28, 2025, 11:20 AM EDT - 3 months ago

CervoMed's Dementia Data Show Slowed Disease Progression

Jul 28, 2025, 7:00 AM EDT - 3 months ago

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Jul 8, 2025, 7:00 AM EDT - 4 months ago

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

May 12, 2025, 8:00 AM EDT - 6 months ago

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Mar 31, 2025, 2:34 PM EDT - 8 months ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CVS GERN LLY NVO SEPN

Mar 25, 2025, 8:00 AM EDT - 8 months ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Mar 22, 2025, 2:55 AM EDT - 8 months ago

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

Mar 10, 2025, 4:05 PM EDT - 8 months ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Jan 29, 2025, 8:00 AM EST - 10 months ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

Dec 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 10, 2024, 11:37 AM EST - 1 year ago

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

Dec 10, 2024, 10:10 AM EST - 1 year ago

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

Dec 10, 2024, 7:33 AM EST - 1 year ago

CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Nov 27, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 8, 2024, 9:55 AM EST - 1 year ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

Nov 4, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Oct 29, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Oct 2, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Aug 22, 2024, 8:00 AM EDT - 1 year ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

Jul 30, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in the Emerging Growth Conference

Jul 11, 2024, 8:51 AM EDT - 1 year ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Jun 11, 2024, 8:00 AM EDT - 1 year ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

May 20, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Appoint William Elder as Chief Financial Officer

May 15, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 2, 2024, 2:59 AM EDT - 1 year ago

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

Apr 1, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Mar 28, 2024, 8:30 AM EDT - 1 year ago

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Mar 5, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Feb 21, 2024, 8:00 AM EST - 1 year ago

CervoMed to Participate in the BIO CEO and Investor Conference

Feb 12, 2024, 8:00 AM EST - 1 year ago

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Feb 7, 2024, 8:30 AM EST - 1 year ago

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Feb 5, 2024, 8:00 AM EST - 1 year ago

CervoMed to Participate in the Emerging Growth Conference 67

Jan 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 66

Nov 13, 2023, 7:00 AM EST - 2 years ago

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 25, 2023, 2:50 PM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

Oct 24, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

Oct 18, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

Oct 5, 2023, 7:00 AM EDT - 2 years ago

CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference

Sep 5, 2023, 7:00 AM EDT - 2 years ago

CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 16, 2023, 1:58 PM EDT - 2 years ago

CervoMed Announces Completion of Merger with EIP Pharma

Aug 15, 2023, 4:01 PM EDT - 2 years ago

Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma

Doki0926 Nov. 13 at 10:08 AM

$CRVO will it go up?

0 · Reply

BPler Nov. 12 at 9:03 PM

$CRVO https://www.marketbeat.com/instant-alerts/cervomed-inc-nasdaqcrvo-receives-consensus-rating-of-moderate-buy-from-brokerages-2025-11-12/

0 · Reply

5layer Nov. 12 at 2:02 PM

$CRVO

0 · Reply

BPler Nov. 12 at 7:02 AM

$CRVO https://beingpatient.com/dementia-with-lewy-bodies-pill-phase-3-clinical-trial/?utm_source=organic&utm_medium=social

1 · Reply

BPler Nov. 12 at 7:00 AM

$CRVO https://www.gurufocus.com/news/3201183/crvo-analyst-jason-kolbert-maintains-buy-rating-with-31-target-crvo-stock-news

0 · Reply

MV0527 Nov. 12 at 1:56 AM

$CRVO

0 · Reply

5layer Nov. 11 at 5:04 PM

$CRVO

1 · Reply

Messerschmittbf109 Nov. 11 at 3:24 PM

$CRVO $JSPR boys .. but really are you thinking positive in this turd full of thi eves ?????

0 · Reply

Messerschmittbf109 Nov. 11 at 1:37 PM

$CRVO rottens tp 4-5 x actual price Rottens

0 · Reply

MV0527 Nov. 11 at 1:15 PM

$CRVO

0 · Reply

JarvisFlow Nov. 11 at 12:24 PM

D. Boral Capital has adjusted their stance on CervoMed ( $CRVO ), setting the rating to Buy with a target price of 31.

1 · Reply

Doom_Gloom_AR Nov. 11 at 3:34 AM

$CRVO stat sig twice in LBD - Lets get this funding for the phase 3. I like how they are taking their time, they might wait for results from the p2 in stroke before doing a funding. The scientific rational for this working in stroke is pretty high - I think it's better then the ftd trial. In PEALut showed stat sig benifits on stroke recovery. I think that bodes well for neflimanipod.

0 · Reply

Messerschmittbf109 Nov. 10 at 8:42 PM

$JSPR How many wages can these beg .g ars still steal? $CRVO …..

1 · Reply

LowCountryHooker Nov. 10 at 5:35 PM

$CRVO Today, we announced our Q3 2025 financial results and provided important updates on the progress of our lead program, neflamapimod. Our recent announcement on our alignment with FDA on a registration path for neflamapimod in dementia with Lewy bodies (DLB), along with our recent clinical trial results, reinforce our urgency toward initiating our phase 3 trial next year and potentially bring the first approved treatment to patients and families affected by this disease. You can read more here: https://lnkd.in/e5jeTQ2W #DLB #Dementia #neflamapimod #Biotech

0 · Reply

Messerschmittbf109 Nov. 10 at 5:01 PM

$CRVO $JSPR the last two bio stocks red today 💩🤡💩

0 · Reply

BPler Nov. 10 at 1:55 PM

$CRVO Company value: "neflamapimod has the potential to transform the treatment landscape for DLB by treating the cognitive and functional decline that defines this devastating disease and that these recent milestones have brought us closer to delivering the first approved therapy for patients with DLB in the United States" Market Value today: Under 65 Mio. $ If they need cash, they will get it. Dilution will not happen and these prices with such a huge insider position and warrants at 39 USD sitting.

1 · Reply

Messerschmittbf109 Nov. 10 at 1:49 PM

$CRVO a lot of cash too

0 · Reply

BPler Nov. 10 at 1:35 PM

$CRVO https://www.globenewswire.com/news-release/2025/11/10/3184371/0/en/CervoMed-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Updates.html

0 · Reply

Disinformation_Consumer Nov. 9 at 7:54 PM

$CRVO their ability to continue as a going concern is in question. Sell everything.

3 · Reply

Messerschmittbf109 Nov. 8 at 4:36 PM

$CRVO CervoMed plans to launch a single, global, randomized, double-blind, placebo-controlled Phase 3 clinical trial to evaluate the efficacy and safety of neflamapimod in approximately 300 patients with DLB according to consensus clinical criteria, in the second half of 2026. In Phase 1 and 2 clinical trials, which involved over 800 participants, the drug was generally well tolerated and showed consistent signs of effectiveness

1 · Reply

Messerschmittbf109 Nov. 8 at 10:24 AM

$CRVO are you short ? Wyatt news is that ?? They are th I ves but your post is ridiculous fir a bio stock.all bio stocks are on this situation

1 · Reply

d_risk Nov. 8 at 2:55 AM

$CRVO - CervoMed Inc. Common Stock - 10Q - Updated Risk Factors CRVO warns ongoing losses raise substantial doubt about its ability to continue as a going concern. #MedicalDevices #Healthcare #Losses #GoingConcern #FinancialRisk 🟢 Added 🟠 Removed https://d-risk.ai/CRVO/10-Q/2025-11-07

1 · Reply

Market Cap	64.49M
Revenue (ttm)	9.74M
Net Income (ttm)	-16.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-167.25%
Debt to Equity Ratio	0.00

Volume	54,700
Avg Vol	95,724
Day's Range	N/A - N/A
Shares Out	9.25M
Stochastic %K	69%
Beta	-0.89
Analysts	Strong Sell
Price Target	$22.57